Company News: BioNTech to present interim PhaseI/II data for investigational mRNA vaccine in melanoma patients at AACR Annual Meeting 2017

First Clinically Applicable, Systemic RNA-based Cancer Vaccine –

BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 – 5 in Washington, DC.

This is the first example of a clinically applied systemic mRNA-based cancer immunotherapy.

Permanent Abstract Number: CT034

Poster:        “A First-in-Human Phase I/II Clinical Trial Assessing Novel mRNA-lipoplex Nanoparticles for Potent Melanoma Immunotherapy”

Date:            Monday, April 3, 2017

Session:       PO.CT01 – Phase I Clinical Trials in Progress

Time:            8:00AM – 12:00PM Eastern Daylight Time

Location:     Poster Section 33


The Phase I/II dose escalation Lipo-MERIT trial (NCT02410733) in melanoma patients assesses the safety and tolerability as well as the potency of inducing antigen-specific immune responses of the first systemic mRNA vaccine to be developed based on BioNTech’s mRNA nanoparticle immunotherapy platform.